1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

26 Jun 2024
Admin
News Article

GSK's Omjjara Receives Approval in Japan for Treating Myelofibrosis

Overview

GSK plc (LSE/NYSE: GSK) announced today that Omjjara (momelotinib) has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for treating myelofibrosis. Omjjara is an oral inhibitor of JAK1/JAK2 and activin A receptor type 1 (ACVR1), taken once daily. This approval marks the fourth major regulatory milestone for momelotinib, following approvals by the US FDA as Ojjaara and under the brand Omjjara by the European Commission and the UK's MHRA.

From the Oncology Strategist: GSK

Nina Mojas, Senior Vice President of Oncology Global Product Strategy at GSK, highlighted the heavy burden of myelofibrosis, which includes symptoms like spleen enlargement, fatigue, night sweats, and bone pain, often accompanied by anaemia requiring frequent blood transfusions.
Mojas noted that the approval of Omjjara provides Japanese myelofibrosis patients with a new treatment option for this challenging blood cancer.

Myelofibrosis: Epidemiology

Myelofibrosis affects approximately 1 in 500,000 people globally, with an estimated 5,000 patients in Japan.
Anaemia is prevalent among these patients and significantly impacts treatment outcomes and quality of life.
The approval of Omjjara was supported by data from the MOMENTUM and SIMPLIFY-1 trials, demonstrating its efficacy and safety in treating myelofibrosis, particularly in anaemic and symptomatic patients.

Omjjara: Mechanism of Action

Omjjara works by inhibiting JAK1, JAK2, and ACVR1 pathways, which can alleviate constitutional symptoms and splenomegaly and potentially benefit anaemia-related conditions by reducing hepcidin levels.

Omjjara’s indications, dosing, and safety considerations in Japan, consult the updated Product Information available through the Japan Pharmaceuticals and Medical Devices Agency.

About Myelofibrosis

Myelofibrosis is a rare blood cancer characterized by disrupted blood cell production due to dysregulated JAK-signal transducer and activator of transcription protein signalling.
Clinical symptoms include enlarged spleen, low blood counts, and debilitating symptoms such as fatigue and bone pain.

About GSK

GSK remains committed to advancing oncology treatments, focusing on innovations in immuno-oncology, targeted therapies, and advancements in hematologic malignancies to improve patient outcomes worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!